Literature DB >> 20953834

Are we missing the mTOR target in breast cancer?

Stephen R D Johnston1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20953834     DOI： 10.1007/s10549-010-1207-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  4 in total

Review 1.  Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.

Authors:  Vassilis Aggelis; Stephen R D Johnston
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

2.  The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.

Authors:  Julia A Beaver; Ben H Park
Journal:  Future Oncol       Date:  2012-06       Impact factor: 3.404

3.  Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation.

Authors:  D M Maruani; T N Spiegel; E N Harris; A S Shachter; H A Unger; S Herrero-González; M K Holz
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

Review 4.  Still Living Better through Chemistry: An Update on Caloric Restriction and Caloric Restriction Mimetics as Tools to Promote Health and Lifespan.

Authors:  Carla Almendáriz-Palacios; Darrell D Mousseau; Christopher H Eskiw; Zoe E Gillespie
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.